Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease - PubMed (original) (raw)
Multicenter Study
. 2011 Mar;106(3):460-8; quiz 469.
doi: 10.1038/ajg.2010.488. Epub 2011 Jan 4.
Collaborators, Affiliations
- PMID: 21206486
- PMCID: PMC3070294
- DOI: 10.1038/ajg.2010.488
Multicenter Study
Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease
Kristin D Kistler et al. Am J Gastroenterol. 2011 Mar.
Abstract
Objectives: Factors that determine disease severity in nonalcoholic fatty liver disease (NAFLD) are unclear, but exercise is a recommended treatment. We evaluated the association between physical activity intensity and histological severity of NAFLD.
Methods: We conducted a retrospective analysis of adults with biopsy-proven NAFLD enrolled in the NASH CRN (Nonalcoholic Steatohepatitis Clinical Research Network). Using self-reported time spent in physical activity, we classified participants as inactive or as meeting the US guidelines for either moderate or vigorous exercise. Histology was reviewed by a central pathology committee. Frequency and odds of steatohepatitis (NASH) and advanced fibrosis were compared between subjects who either met or did not meet exercise recommendations, and by the total amount of exercise per week.
Results: A total of 813 adults (males=302, females=511) with NAFLD were included, with a mean age of 48 years. Neither moderate-intensity exercise nor total exercise per week was associated with NASH or stage of fibrosis. Meeting vigorous recommendations was associated with a decreased adjusted odds of having NASH (odds ratio (OR): 0.65 (0.43-0.98)). Doubling the recommended time spent in vigorous exercise, as is suggested for achieving additional health benefits, was associated with a decreased adjusted odds of advanced fibrosis (OR: 0.53 (0.29-0.97)).
Conclusions: These data support an association of vigorous but not moderate or total exercise with the severity of NAFLD. Optimal doses of exercise by duration and intensity for the prevention or treatment of NASH have not been established; however, intensity may be more important than duration or total volume.
Figures
Figure 1
Inclusion and exclusion flow chart. MET, metabolic equivalent; NASH CRN, Nonalcoholic Steatohepatitis Clinical Research Network. PA, physical activity.
Comment in
- Editorial: Exercise for NAFLD: does intensity matter?
Conjeevaram HS, Tiniakos DG. Conjeevaram HS, et al. Am J Gastroenterol. 2011 Mar;106(3):470-5. doi: 10.1038/ajg.2010.496. Am J Gastroenterol. 2011. PMID: 21378763
Similar articles
- Ethnicity and nonalcoholic fatty liver disease.
Bambha K, Belt P, Abraham M, Wilson LA, Pabst M, Ferrell L, Unalp-Arida A, Bass N; Nonalcoholic Steatohepatitis Clinical Research Network Research Group. Bambha K, et al. Hepatology. 2012 Mar;55(3):769-80. doi: 10.1002/hep.24726. Hepatology. 2012. PMID: 21987488 Free PMC article. - Editorial: Exercise for NAFLD: does intensity matter?
Conjeevaram HS, Tiniakos DG. Conjeevaram HS, et al. Am J Gastroenterol. 2011 Mar;106(3):470-5. doi: 10.1038/ajg.2010.496. Am J Gastroenterol. 2011. PMID: 21378763 - Association between metabolic syndrome and liver histology among children with nonalcoholic Fatty liver disease.
Patton HM, Yates K, Unalp-Arida A, Behling CA, Huang TT, Rosenthal P, Sanyal AJ, Schwimmer JB, Lavine JE. Patton HM, et al. Am J Gastroenterol. 2010 Sep;105(9):2093-102. doi: 10.1038/ajg.2010.152. Epub 2010 Apr 6. Am J Gastroenterol. 2010. PMID: 20372110 Free PMC article. - Can NASH be diagnosed, graded, and staged noninvasively?
Grandison GA, Angulo P. Grandison GA, et al. Clin Liver Dis. 2012 Aug;16(3):567-85. doi: 10.1016/j.cld.2012.05.001. Epub 2012 Jun 26. Clin Liver Dis. 2012. PMID: 22824481 Free PMC article. Review. - Clinical relevance of liver histopathology and different histological classifications of NASH in adults.
Nascimbeni F, Ballestri S, Machado MV, Mantovani A, Cortez-Pinto H, Targher G, Lonardo A. Nascimbeni F, et al. Expert Rev Gastroenterol Hepatol. 2018 Apr;12(4):351-367. doi: 10.1080/17474124.2018.1415756. Epub 2017 Dec 26. Expert Rev Gastroenterol Hepatol. 2018. PMID: 29224471 Review.
Cited by
- Exercise intensity and mortality in overweight and obese patients with chronic kidney disease: longitudinal analysis (1999-2016).
Qian C, Zhou F, Lu D, Huang J, Sun M. Qian C, et al. BMC Public Health. 2024 Oct 31;24(1):3020. doi: 10.1186/s12889-024-20498-6. BMC Public Health. 2024. PMID: 39482632 Free PMC article. - Rapid improvement of hepatic steatosis and liver stiffness after metabolic/bariatric surgery: a prospective study.
Nixdorf L, Hartl L, Ströhl S, Felsenreich DM, Mairinger M, Jedamzik J, Richwien P, Mozayani B, Semmler G, Balcar L, Schwarz M, Jachs M, Dominik N, Bichler C, Trauner M, Mandorfer M, Reiberger T, Langer FB, Bauer DJM, Prager G. Nixdorf L, et al. Sci Rep. 2024 Jul 30;14(1):17558. doi: 10.1038/s41598-024-67415-w. Sci Rep. 2024. PMID: 39080285 Free PMC article. - Management of Metabolic-Associated Fatty Liver Disease/Metabolic Dysfunction-Associated Steatotic Liver Disease: From Medication Therapy to Nutritional Interventions.
Beygi M, Ahi S, Zolghadri S, Stanek A. Beygi M, et al. Nutrients. 2024 Jul 11;16(14):2220. doi: 10.3390/nu16142220. Nutrients. 2024. PMID: 39064665 Free PMC article. Review. - Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Elshaer A, Chascsa DMH, Lizaola-Mayo BC. Elshaer A, et al. Life (Basel). 2024 Jul 3;14(7):844. doi: 10.3390/life14070844. Life (Basel). 2024. PMID: 39063598 Free PMC article. Review. - Efficacy of orlistat in obese patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.
Mahmoud A, Mohamed I, Abuelazm M, Ahmed AAS, Saeed A, Elshinawy M, Almaadawy O, Abdelazeem B. Mahmoud A, et al. Proc (Bayl Univ Med Cent). 2024 Apr 9;37(4):603-612. doi: 10.1080/08998280.2024.2335829. eCollection 2024. Proc (Bayl Univ Med Cent). 2024. PMID: 38910819 Free PMC article. Review.
References
- Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98:960–7. - PubMed
- Kim WR, Brown RS, Jr, Terrault NA, et al. Burden of liver disease in the United States: summary of aworkshop. Hepatology. 2002;36:227–42. - PubMed
- Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferases activity in the United States in 1999–2002. Am J Gastroenterol. 2006;101:76–82. - PubMed
- Bell BP, Manos MM, Zaman A, et al. The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance. Am J Gastroenterol. 2008;103:2727–36. - PubMed
- Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008;28:339–50. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- UL1RR02501401/RR/NCRR NIH HHS/United States
- U01DK061713/DK/NIDDK NIH HHS/United States
- U01 DK061732/DK/NIDDK NIH HHS/United States
- U01DK061737/DK/NIDDK NIH HHS/United States
- U01DK061728/DK/NIDDK NIH HHS/United States
- M01 RR000065/RR/NCRR NIH HHS/United States
- U01 DK061732-09/DK/NIDDK NIH HHS/United States
- M01RR000827/RR/NCRR NIH HHS/United States
- U01 DK061737/DK/NIDDK NIH HHS/United States
- U01 DK061713/DK/NIDDK NIH HHS/United States
- UL1 RR024989/RR/NCRR NIH HHS/United States
- U01 DK061734-07/DK/NIDDK NIH HHS/United States
- U01DK061731/DK/NIDDK NIH HHS/United States
- U01 DK061731-09/DK/NIDDK NIH HHS/United States
- U01 DK061731/DK/NIDDK NIH HHS/United States
- U01 DK061718/DK/NIDDK NIH HHS/United States
- M01RR000065/RR/NCRR NIH HHS/United States
- UL1 RR024131/RR/NCRR NIH HHS/United States
- U01DK061718/DK/NIDDK NIH HHS/United States
- U01 DK061713-09/DK/NIDDK NIH HHS/United States
- U01DK061732/DK/NIDDK NIH HHS/United States
- M01 RR000750/RR/NCRR NIH HHS/United States
- U01 DK061730/DK/NIDDK NIH HHS/United States
- U01 DK061738-09/DK/NIDDK NIH HHS/United States
- U01 DK061728/DK/NIDDK NIH HHS/United States
- ULRR02413101/PHS HHS/United States
- UL1 RR025014/RR/NCRR NIH HHS/United States
- UL1 RR025014-01/RR/NCRR NIH HHS/United States
- U01 DK061738/DK/NIDDK NIH HHS/United States
- UL1RR024989/RR/NCRR NIH HHS/United States
- UL1 RR024131-01/RR/NCRR NIH HHS/United States
- U01 DK061734/DK/NIDDK NIH HHS/United States
- U01 DK061730-09/DK/NIDDK NIH HHS/United States
- U01DK061738/DK/NIDDK NIH HHS/United States
- U01 DK061728-09/DK/NIDDK NIH HHS/United States
- M01 RR000827/RR/NCRR NIH HHS/United States
- U01DK061734/DK/NIDDK NIH HHS/United States
- U01 DK061718-09/DK/NIDDK NIH HHS/United States
- U01 DK061737-08/DK/NIDDK NIH HHS/United States
- U01DK061730/DK/NIDDK NIH HHS/United States
- M01RR000750/RR/NCRR NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous